NCT05961670

Brief Summary

Premature infants are more likely to develop hypoxemia after birth often requiring invasive and Non-Invasive Mechanical ventilation and surfactant therapy to improve alveolar gas exchange and oxygen transport. Near-infrared spectroscopy (NIRS) has been used to detect pulmonary regional oxygen saturation (rpSO 2 ) as well as cerebral regional oxygen saturation (rcSO2 ) and evaluate the oxygenation state of the lung and brain. This is a prospective observational study to evaluate utility of rpSO2 and compare it with rcSO2 in preterm infants born between 23-32 weeks of gestation receiving noninvasive ventilation and surfactant treatment. Enrolled patients will be continuously studied with placement of NIRS monitor using cerebral sensor (INVOS™) for 6 hrs and 15 min before and after surfactant administration. Pulmonary regional oxygen saturation (rpSO2) with a sampling interval of 6 s will be followed for 6hrs.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Aug 2023

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 18, 2023

Completed
9 days until next milestone

First Posted

Study publicly available on registry

July 27, 2023

Completed
5 days until next milestone

Study Start

First participant enrolled

August 1, 2023

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2024

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2024

Completed
Last Updated

July 27, 2023

Status Verified

July 1, 2023

Enrollment Period

11 months

First QC Date

July 18, 2023

Last Update Submit

July 18, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • rpSO2 before and after surfactant therapy

    brain and lung rpSO2 will be compared before and after surfactant administration

    6 hours

Secondary Outcomes (2)

  • variations on rpSO2 and rcSO2 during changes in ventilation modes

    6 hours

  • correlation between rpSO2L and SpO2/FiO2 ratio, a/APO2, and O.I

    6 hours

Interventions

Premature infants will be studied with brain and lung NIRS before and after surfactant administration

Eligibility Criteria

Age1 Hour - 24 Hours
Sexall
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

Inborn premature infants

You may qualify if:

  • Infants born between 23-32 weeks of gestation admitted to the Neonatal Intensive Care Unit with respiratory distress receiving non-invasive ventilation and requiring Surfactant Replacement Therapy.

You may not qualify if:

  • Neonates with no need for respiratory support/Surfactant. Neonates with congenital malformations.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Los Angeles General Medical Center

Los Angeles, California, 90033, United States

Location

MeSH Terms

Conditions

Respiratory Distress Syndrome, Newborn

Condition Hierarchy (Ancestors)

Respiratory Distress SyndromeLung DiseasesRespiratory Tract DiseasesRespiration DisordersInfant, Premature, DiseasesInfant, Newborn, DiseasesCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Central Study Contacts

Manoj Biniwale, MD

CONTACT

Rangasamy Ramanathan, MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor of Pediatrics

Study Record Dates

First Submitted

July 18, 2023

First Posted

July 27, 2023

Study Start

August 1, 2023

Primary Completion

June 30, 2024

Study Completion

September 30, 2024

Last Updated

July 27, 2023

Record last verified: 2023-07

Locations